Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences (Nasdaq: RNA), a biopharmaceutical company focused on developing RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), announced its participation in the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024. The presentation will occur at 8:20 a.m. PT/11:20 a.m. ET. A live webcast and replay of the event will be accessible on Avidity’s investor relations webpage.
- Avidity Biosciences will participate in a key industry event, potentially increasing investor awareness.
- The company's focus on Antibody Oligonucleotide Conjugates (AOCs™) highlights its innovative approach in the biopharmaceutical sector.
- Event participation could lead to new investor interest and partnerships.
- The announcement lacks specific details on financial performance or clinical trial updates, which might be important for investor decisions.
- There is no information on potential revenue or market impact from the event participation.
- TD Cowen Genetic Medicines & RNA Summit on June 20 at 8:20 a.m. PT/11:20 a.m. ET
A live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in
Investor Contact:
Geoffrey Grande, CFA
(619) 837-5014
investors@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302172606.html
SOURCE Avidity Biosciences, Inc.
FAQ
What event will Avidity Biosciences participate in on June 20, 2024?
What time is Avidity Biosciences presenting at the TD Cowen Genetic Medicines & RNA Summit?
Where can I watch the live webcast of Avidity Biosciences' presentation on June 20, 2024?
What is the stock symbol for Avidity Biosciences?
What are Antibody Oligonucleotide Conjugates (AOCs™)?
